It is the first such combination to be approved by the Drugs Controller General of India (DCGI) and has completed a multi-centre clinical trial data on Indian patients, Dr Reddy's stated in a press release.
The Atorvastatin market is currently valued at Rs 300 crore and is growing at over 34 per cent annually. The Ramipril market is about Rs 145 crore, growing at over 15 per cent annually, the company said.
The new product is available in two fixed dose combinations of Atocor-R 2.5 (Atorvastatin 10 mg + Ramipril 2.5 mg ) and Atocor-R 5 (Atorvastatin 10 mg + Ramipril 5 mg) and comes in packs of 10.
